Panelists discuss how current risk stratification systems, particularly the European Leukemia Net 2022 classification for intensive therapy and the 2024 classification for lower intensity treatments, ...
Recent years have brought a more targeted approach to treating acute myeloid leukemia (AML) based on accumulating knowledge about the genetic makeup of the heterogenous disease. “Over the past decade, ...
The ASAP trial sets new perspectives on international therapy standards: High-dose chemotherapy is not always necessary before transplantation in cases of acute myeloid leukemia (AML). This means ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback